Jason C Chang1, Lei Zhang1, Alexander E Drilon2, Ping Chi3, Rita Alaggio4, Laetitia Borsu1, Ryma Benayed1, William D Travis1, Marc Ladanyi5, Cristina R Antonescu6. 1. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York. 4. Department of Pathology, University Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: antonesc@mskcc.org.
Abstract
INTRODUCTION: Half of inflammatory myofibroblastic tumors (IMTs) regardless of anatomic location harbor anaplastic lymphoma kinase gene (ALK) rearrangements and overexpress anaplastic lymphoma kinase protein. The wide application of next-generation sequencing and the clinical benefit to tyrosine kinase inhibitors have opened new opportunities for investigation of ALK-negative IMTs. METHODS: In this study, we have investigated a series of pediatric and adult thoracic IMTs for abnormalities in a wide spectrum of actionable kinases by applying a variety of molecular and next-generation sequencing techniques, including fluorescence in situ hybridization (FISH), targeted RNA sequencing, and NanoString assay. RESULTS: There were 33 patients with thoracic IMTs, including five children; their mean age was 37. The tumors showed a monomorphic spindle cell phenotype, except for one with an epithelioid morphologic pattern and moderate to severe atypia. By immunohistochemistry, 24 tumors were ALK positive, and 19 of the 24 showed ALK rearrangements and one ret proto-oncogene gene (RET) rearrangement by FISH. RNA sequencing was performed in the remaining four cases lacking ALK abnormalities by FISH, revealing ALK fusions involving tropomyosin 4 gene (TMP4) and echinoderm microtubule associated protein like 4 gene (EML4) as partner in three cases. NanoString assay was performed in the remaining case, revealing ALK alternative transcription initiation (ALKATI). Nine cases lacking ALK abnormalities were further tested by FISH or targeted RNA sequencing, revealing ROS1 rearrangement in six cases and ETS variant 6 gene (ETV6)-neurotrophic receptor tyrosine kinase 3 gene (NTRK3) fusion in three cases, respectively. CONCLUSIONS: By using a battery of complementary molecular techniques, we have shown that all the thoracic IMTs harbored a tyrosine kinase abnormality, with 30% involving a kinase gene other than ALK, including ROS1, NTRK3, and RET gene fusions. We have also described for the first time ALKATI-induced ALK oncogenic activation in IMTs.
INTRODUCTION: Half of inflammatory myofibroblastic tumors (IMTs) regardless of anatomic location harbor anaplastic lymphoma kinase gene (ALK) rearrangements and overexpress anaplastic lymphoma kinase protein. The wide application of next-generation sequencing and the clinical benefit to tyrosine kinase inhibitors have opened new opportunities for investigation of ALK-negative IMTs. METHODS: In this study, we have investigated a series of pediatric and adult thoracic IMTs for abnormalities in a wide spectrum of actionable kinases by applying a variety of molecular and next-generation sequencing techniques, including fluorescence in situ hybridization (FISH), targeted RNA sequencing, and NanoString assay. RESULTS: There were 33 patients with thoracic IMTs, including five children; their mean age was 37. The tumors showed a monomorphic spindle cell phenotype, except for one with an epithelioid morphologic pattern and moderate to severe atypia. By immunohistochemistry, 24 tumors were ALK positive, and 19 of the 24 showed ALK rearrangements and one ret proto-oncogene gene (RET) rearrangement by FISH. RNA sequencing was performed in the remaining four cases lacking ALK abnormalities by FISH, revealing ALK fusions involving tropomyosin 4 gene (TMP4) and echinoderm microtubule associated protein like 4 gene (EML4) as partner in three cases. NanoString assay was performed in the remaining case, revealing ALK alternative transcription initiation (ALKATI). Nine cases lacking ALK abnormalities were further tested by FISH or targeted RNA sequencing, revealing ROS1 rearrangement in six cases and ETS variant 6 gene (ETV6)-neurotrophic receptor tyrosine kinase 3 gene (NTRK3) fusion in three cases, respectively. CONCLUSIONS: By using a battery of complementary molecular techniques, we have shown that all the thoracic IMTs harbored a tyrosine kinase abnormality, with 30% involving a kinase gene other than ALK, including ROS1, NTRK3, and RET gene fusions. We have also described for the first time ALKATI-induced ALK oncogenic activation in IMTs.
Authors: Cristina R Antonescu; Albert J H Suurmeijer; Lei Zhang; Yun-Shao Sung; Achim A Jungbluth; William D Travis; Hikmat Al-Ahmadie; Christopher D M Fletcher; Rita Alaggio Journal: Am J Surg Pathol Date: 2015-07 Impact factor: 6.394
Authors: Yu-Chien Kao; Christopher D M Fletcher; Rita Alaggio; Leonard Wexler; Lei Zhang; Yun-Shao Sung; Dicle Orhan; Wei-Chin Chang; David Swanson; Brendan C Dickson; Cristina R Antonescu Journal: Am J Surg Pathol Date: 2018-01 Impact factor: 6.394
Authors: Alexander Drilon; Theodore W Laetsch; Shivaani Kummar; Steven G DuBois; Ulrik N Lassen; George D Demetri; Michael Nathenson; Robert C Doebele; Anna F Farago; Alberto S Pappo; Brian Turpin; Afshin Dowlati; Marcia S Brose; Leo Mascarenhas; Noah Federman; Jordan Berlin; Wafik S El-Deiry; Christina Baik; John Deeken; Valentina Boni; Ramamoorthy Nagasubramanian; Matthew Taylor; Erin R Rudzinski; Funda Meric-Bernstam; Davendra P S Sohal; Patrick C Ma; Luis E Raez; Jaclyn F Hechtman; Ryma Benayed; Marc Ladanyi; Brian B Tuch; Kevin Ebata; Scott Cruickshank; Nora C Ku; Michael C Cox; Douglas S Hawkins; David S Hong; David M Hyman Journal: N Engl J Med Date: 2018-02-22 Impact factor: 91.245
Authors: Kyuichi Kadota; Kei Suzuki; Stefan S Kachala; Emily C Zabor; Camelia S Sima; Andre L Moreira; Akihiko Yoshizawa; Gregory J Riely; Valerie W Rusch; Prasad S Adusumilli; William D Travis Journal: Mod Pathol Date: 2012-04-13 Impact factor: 7.842
Authors: Sara M Falzarano; Jesse K McKenney; Rodolfo Montironi; John N Eble; Adeboye O Osunkoya; Juan Guo; Shengmei Zhou; Hong Xiao; Saravana M Dhanasekaran; Sudhanshu Shukla; Rohit Mehra; Cristina Magi-Galluzzi Journal: Am J Surg Pathol Date: 2016-07 Impact factor: 6.394
Authors: Ali H Alassiri; Rola H Ali; Yaoqing Shen; Amy Lum; Caron Strahlendorf; Rebecca Deyell; Rod Rassekh; Poul H Sorensen; Janessa Laskin; Marco Marra; Stephen Yip; Cheng-Han Lee; Tony L Ng Journal: Am J Surg Pathol Date: 2016-08 Impact factor: 6.394
Authors: Thomas Wiesner; William Lee; Anna C Obenauf; Leili Ran; Rajmohan Murali; Qi Fan Zhang; Elissa W P Wong; Wenhuo Hu; Sasinya N Scott; Ronak H Shah; Iñigo Landa; Julia Button; Nathalie Lailler; Andrea Sboner; Dong Gao; Devan A Murphy; Zhen Cao; Shipra Shukla; Travis J Hollmann; Lu Wang; Laetitia Borsu; Taha Merghoub; Gary K Schwartz; Michael A Postow; Charlotte E Ariyan; James A Fagin; Deyou Zheng; Marc Ladanyi; Klaus J Busam; Michael F Berger; Yu Chen; Ping Chi Journal: Nature Date: 2015-10-07 Impact factor: 49.962
Authors: Ramamoorthy Nagasubramanian; Julie Wei; Paul Gordon; Jeff C Rastatter; Michael C Cox; Alberto Pappo Journal: Pediatr Blood Cancer Date: 2016-04-19 Impact factor: 3.167
Authors: Giacomo Giulio Baldi; Mehdi Brahmi; Salvatore Lo Vullo; Elena Cojocaru; Olivier Mir; Michela Casanova; Bruno Vincenzi; Tommaso Martino De Pas; Giovanni Grignani; Maria Abbondanza Pantaleo; Jean Yves Blay; Robin Lewis Jones; Axel Le Cesne; Anna Maria Frezza; Alessandro Gronchi; Paola Collini; Angelo Paolo Dei Tos; Carlo Morosi; Luigi Mariani; Paolo Giovanni Casali; Silvia Stacchiotti Journal: Oncologist Date: 2020-07-12
Authors: Mrinal M Gounder; Narasimhan P Agaram; Sally E Trabucco; Victoria Robinson; Richard A Ferraro; Sherri Z Millis; Anita Krishnan; Jessica Lee; Steven Attia; Wassim Abida; Alexander Drilon; Ping Chi; Sandra P D' Angelo; Mark A Dickson; Mary Lou Keohan; Ciara M Kelly; Mark Agulnik; Sant P Chawla; Edwin Choy; Rashmi Chugh; Christian F Meyer; Parvathi A Myer; Jessica L Moore; Ross A Okimoto; Raphael E Pollock; Vinod Ravi; Arun S Singh; Neeta Somaiah; Andrew J Wagner; John H Healey; Garrett M Frampton; Jeffrey M Venstrom; Jeffrey S Ross; Marc Ladanyi; Samuel Singer; Murray F Brennan; Gary K Schwartz; Alexander J Lazar; David M Thomas; Robert G Maki; William D Tap; Siraj M Ali; Dexter X Jin Journal: Nat Commun Date: 2022-06-15 Impact factor: 17.694
Authors: Bin Xu; Albert J H Suurmeijer; Narasimhan P Agaram; Lei Zhang; Cristina R Antonescu Journal: Histopathology Date: 2021-05-19 Impact factor: 7.778
Authors: G D Demetri; C R Antonescu; B Bjerkehagen; J V M G Bovée; K Boye; M Chacón; A P Dei Tos; J Desai; J A Fletcher; H Gelderblom; S George; A Gronchi; R L Haas; N Hindi; P Hohenberger; H Joensuu; R L Jones; I Judson; Y-K Kang; A Kawai; A J Lazar; A Le Cesne; R Maestro; R G Maki; J Martín; S Patel; F Penault-Llorca; C Premanand Raut; P Rutkowski; A Safwat; M Sbaraglia; I-M Schaefer; L Shen; C Serrano; P Schöffski; S Stacchiotti; K Sundby Hall; W D Tap; D M Thomas; J Trent; C Valverde; W T A van der Graaf; M von Mehren; A Wagner; E Wardelmann; Y Naito; J Zalcberg; J-Y Blay Journal: Ann Oncol Date: 2020-09-03 Impact factor: 32.976